Kyongbo Pharmaceutical Co., Ltd
KRX:214390.KS
7440 (KRW) • At close March 27, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||||
| Net Income
| 2,974.4 | 610.59 | -7,495.179 | 9,404.446 | 5,285.239 | 13,116.049 | 17,963.31 | 12,705.93 | 26,109.623 | 8,635.954 |
| Depreciation & Amortization
| 11,698.82 | 11,935.736 | 12,756.697 | 12,587.944 | 12,589.155 | 11,557.87 | 11,467.456 | 10,439.747 | 8,278.588 | 7,202.625 |
| Deferred Income Tax
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change In Working Capital
| -13,680.965 | -2,953.45 | 10,942.426 | -3,460.281 | 7,018.753 | -23,399.183 | -9,604.672 | 1,235.78 | -10,644.746 | -11,542.894 |
| Accounts Receivables
| -6,304.841 | -1,967.079 | 6,392.447 | -3,011.066 | 14,777.304 | -13,375.128 | -6,790.674 | 2,649.889 | 0 | 0 |
| Inventory
| -16,279.602 | -274.286 | 3,932.687 | -380.18 | -9,305.248 | -5,386.953 | -452.911 | 1,943.227 | -6,534.538 | -10,408.764 |
| Accounts Payables
| 8,255.52 | -1,561.558 | 2,096.813 | -960.457 | 327.007 | -427.254 | -211.881 | -915.28 | 0 | 0 |
| Other Working Capital
| 647.958 | 849.473 | -1,479.521 | 891.422 | 1,219.69 | -18,012.23 | -9,151.761 | -707.447 | -4,110.208 | -1,134.13 |
| Other Non Cash Items
| 3,852.065 | 533.855 | 1,763.959 | 2,263.118 | -1,225.036 | -2,412.896 | 5,979.052 | 947.346 | -19,503.323 | 11,746.182 |
| Operating Cash Flow
| 4,844.32 | 10,126.731 | 17,967.903 | 20,795.227 | 23,668.111 | -1,138.159 | 25,805.146 | 25,328.803 | 4,240.142 | 16,041.867 |
| Investing Activities: | ||||||||||
| Investments In Property Plant And Equipment
| -10,877.137 | -13,183.82 | -18,323.508 | -12,436.546 | -23,246.138 | -8,194.652 | -7,396.604 | -19,684.026 | -27,260.755 | -19,280.196 |
| Acquisitions Net
| 21.879 | -2,400 | -1,326.318 | -304.438 | -4,200 | 0 | 999.918 | 20.265 | -338.337 | -905.115 |
| Purchases Of Investments
| -8,928.503 | -870 | -7,739.56 | -9,543.262 | -4,200 | 0 | 0 | -540 | -727.361 | -720 |
| Sales Maturities Of Investments
| 5,745.829 | 1,590.159 | 11,188.505 | 2,346.207 | 4,200 | 0 | 999.918 | 0 | 187.426 | 1,516.449 |
| Other Investing Activites
| -229.939 | -13.537 | 27.312 | 260.281 | -681.425 | 0 | 0.712 | 65.265 | 357.085 | 930.247 |
| Investing Cash Flow
| -14,267.871 | -14,877.198 | -16,173.569 | -19,677.758 | -28,127.563 | -8,194.652 | -6,395.974 | -20,158.761 | -27,781.942 | -18,458.614 |
| Financing Activities: | ||||||||||
| Debt Repayment
| -9,125.93 | -140,188.425 | -151,349.386 | -146,871.205 | -72,474.561 | -67,493.972 | -97,436.419 | -115,519.088 | -143,582.234 | -117,751.182 |
| Common Stock Issued
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35,475.952 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 135,333.666 | 0 |
| Dividends Paid
| -1,195.343 | -1,195.343 | -2,390.686 | -2,390.686 | -4,781.372 | 0 | -4,781.372 | -6,574.387 | -6,454.851 | -6,454.851 |
| Other Financing Activities
| 17,480.425 | 147,972.489 | 144,518.318 | 153,680.108 | 83,366.607 | 81,289.685 | 85,375.376 | 117,273.031 | -0 | 128,711.902 |
| Financing Cash Flow
| 7,159.152 | 6,588.722 | -9,221.753 | 4,418.217 | 6,110.674 | 7,818.998 | -16,842.415 | -4,820.443 | 20,772.532 | 4,505.868 |
| Other Information: | ||||||||||
| Effect Of Forex Changes On Cash
| 392.976 | 219.914 | 278.446 | -865.231 | 131.731 | 96.038 | -743.413 | -173.763 | 220.782 | -70.678 |
| Net Change In Cash
| -1,871.423 | 2,058.168 | -7,148.974 | 4,670.456 | 1,782.952 | -1,417.775 | 1,823.343 | 175.835 | -2,548.485 | 2,018.443 |
| Cash At End Of Period
| 4,477.057 | 6,348.48 | 4,290.311 | 11,439.285 | 6,768.829 | 4,985.877 | 6,403.652 | 4,580.309 | 4,404.474 | 6,952.959 |